SCHEMBL5000002

SCHEMBL5000002

C[C@@H](NCc1ccc(Cl)c(NC(=O)C(C)(C)C)c1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
MAPK1 P28482 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MITF O75030 1/20 0.44
HPGD P15428 1/20 0.44
KLF5 Q13887 1/20 0.44
HTT P42858 2/20 0.43
NPC1 O15118 1/20 0.43
ALOX12 P18054 1/20 0.43
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
NPY2R P49146 1/20 0.40
HDAC1 Q13547 1/20 0.40
APAF1 O14727 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4999756 0.88 SMN1; SMN2 (0.52) MEN1KMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL4996347 0.87 SMN1; SMN2 (0.48) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL4990054 0.85 HDAC1 (0.53) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL4999861 0.85 ALDH1A1 (0.48) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL4540403 0.85 HDAC1 (0.53) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL4999697 0.85 ALDH1A1 (0.48) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL4999764 0.84 SMN1; SMN2 (0.51) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL4540963 0.82 ALDH1A1 (0.57) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL4999636 0.82 ALDH1A1 (0.57) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL14074032 0.81 NPC1 (0.48) MEN1KMT2ARAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221101-A1 Calcium receptor modulating agents AMGEN INC. (US) 2008-09-11 US claimed
US-8349831-B2 Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion AMGEN INC. (US) 2013-01-08 US disclosed
US-8349831-B2 Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion AMGEN INC. (US) 2013-01-08 US disclosed
US-8349831-B2 Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion AMGEN INC. (US) 2013-01-08 US disclosed
US-20080221101-A1 Calcium receptor modulating agents AMGEN INC. (US) 2008-09-11 US disclosed
US-20080221101-A1 Calcium receptor modulating agents AMGEN INC. (US) 2008-09-11 US disclosed
US-20080221101-A1 Calcium receptor modulating agents AMGEN INC. (US) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221101-A1 Calcium receptor modulating agents CASR, RYR1, RYR2 MEN1 2531/4885KMT2A 4786/4885RAB9A 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.